Combination enoxaparin-abciximab therapy during coronary intervention: the next standard of care?
Tramuta
D A
DA
The Carl and Edyth Lindner Center for Research and Education, 2123 Auburn Avenue, Suite #424, Cincinnati, OH 45219, USA.
Kereiakes
D J
DJ
Dippel
E J
EJ
Lengerich
R
R
Broderick
T M
TM
Abbottsmith
C W
CW
Whang
D D
DD
Roth
E M
EM
Schneider
J F
JF
Howard
W
W
Shimshak
T M
TM
D000077284:Abciximab; D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D017023:Coronary Angiography; D001026:Coronary Artery Bypass / Q000009:adverse effects* / Q000379:methods; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000601:surgery; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D017984:Enoxaparin / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000628:therapy*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014654:Vascular Patency
D000911:Antibodies, Monoclonal; D017984:Enoxaparin; D007140:Immunoglobulin Fab Fragments; D000077284:Abciximab